Peter C. Enzinger, MD
Dana-Farber Cancer Institute
5
5
5
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Xiaoli Lan, PhD
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shared therapeutic areas:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Gary K. Schwartz, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
howard Safran, MD
Brown University
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Steven R. Alberts, MD
Mayo Clinic
Shared therapeutic areas:
yuankai shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Pembrolizumab in Refractory Advanced Esophageal Cancer
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
All 5 trials loaded